Though tetanus is regarded as a third world disease, the disease is not eradicated from the developed world. In fact, a subgroup of the population, especially the elderly, in the developed world may be susceptible to the disease 1 . The mortality from tetanus ranges from 15 to 40% depending on the severity of illness and availability of intensive care 2, 3 . The common causes for mortality in tetanus are severe cardiovascular dysfunction as well as the complications of long-term sedation and artificial ventilation, such as pulmonary sepsis leading to acute respiratory distress syndrome or septic shock 4 . Despite the continuing search for drugs that can control spasms and autonomic dysfunction without heavy sedation and artificial ventilation, there has not been much success. Though various newer pharmacological agents have been reported to be useful, there is a paucity of randomised controlled trials assessing the benefits of alternative therapies over conventional sedation and paralysis 5 .
Magnesium was first used in the treatment of tetanus almost 100 years ago 6 and since 1985 there have been various case reports 7 and case series 4, 5, 8, 9 describing its utility to control spasms, reduce rigidity and stabilise the sympathetic dysfunction of tetanus. Attygalle and Rodrigo 4,5 from Sri Lanka reported two series about their experience of magnesium in tetanus to suggest that magnesium can be used as the sole agent for the control of spasms in tetanus without the need for sedation and artificial ventilation. However, others have not confirmed this.
The pharmacological rationale for use of magnesium in tetanus is based on its property of physiological calcium antagonism and depression of neural transmission. The correlation between depression of neuromuscular transmission and serum magnesium concentration has been established to be safe at a therapeutic range of 2 to 4 mmol/l in eclampsia 10, 11 and this has been extrapolated to tetanus. Some authors 3 have been concerned about the risk of muscle weakness induced by continuous infusions of magnesium that may paradoxically increase the requirement for SuMMARy There are reports that suggest that magnesium sulphate alone may control muscle spasms thereby avoiding sedation and mechanical ventilation in tetanus, but this has not been confirmed. We examined the efficacy and safety of intravenous magnesium sulphate for control of rigidity and spasms in adults with tetanus.
A prospective clinical study of intravenous magnesium sulphate was carried out over a period of two years in a tertiary care teaching hospital. In addition to human tetanus immunoglobulin and parenteral antibiotics, patients with tetanus received magnesium sulphate 70 mg/kg intravenously followed by infusion. The infusion was increased by 0.5 g/hour every six hours until cessation of spasms or abolishment of patellar tendon jerk. The primary outcome measure was efficacy determined by control of spasms. Secondary outcomes included frequency of autonomic instability, duration of ventilatory support, hospital stay and mortality.
Thirty-three patients were enrolled. At presentation, the incidence of severity of tetanus was as follows: Grade I: 5 (15%), Grade II: 13 (39%), Grade III: 14 (42%) and Grade IV: 1 (3%). Rigidity and mild spasms were controlled with magnesium therapy alone in six patients; all were Grades I or II. Additional sedatives were required in severe forms of tetanus. The average duration of ventilatory support was 18.3±16.0 days and the overall mortality was 22.9%. Asymptomatic hypocalcaemia was a universal finding.
Magnesium sulphate therapy alone may not be efficacious for the treatment of severe tetanus.
mechanical ventilatory support. The only randomised controlled trial 3 available on this topic found that magnesium infusion does not reduce the need for mechanical ventilation in adults with severe tetanus though it may reduce the requirement of other drugs to control muscle spasms 5,9 . Our unit manages all patients with adult tetanus presenting to the Postgraduate Institute for Medical Education and Research, a tertiary care teaching hospital in Northern India and has approximately 18 to 22 admissions in a year. This number is far too small to conduct a randomised controlled trial to assess the efficacy of magnesium intervention in a reasonable period of time. Therefore we aimed to study the utility of magnesium infusion for control of rigidity, spasms and autonomic instability in our cohort of patients in a prospective manner.
MATERIALS AND METHODS
After approval of the Institutional Ethics Committee, a prospective clinical trial was designed. All adult patients diagnosed as having tetanus in the Postgraduate Institute for Medical Education and Research were admitted to the adult tetanus care unit. The patients admitted from 1 January 2006 to 31 December 2007 were enrolled in the study after obtaining written informed consent from the patient or the relative where the patient was unable to give consent. Patients with compromised renal function as defined by serum creatinine more than 0.8 mmol/l or urine output less than 1 ml/kg/hour were excluded from the trial. Those with electrocardiogram evidence of conduction abnormality or systolic blood pressure less than 80 mmHg unresponsive to fluid challenge and those on haemodynamic support were also excluded.
Patients received intramuscular human tetanus immunoglobulin and tetanus toxoid on admission. Metronidazole was started intravenously in all and surgical debridement was performed if a wound was present. Protection of the airway was achieved with tracheostomy in patients with spasms. Intravenous magnesium sulphate was started in all patients after a loading dose of 70 mg/kg over 30 minutes followed by infusion at 2.0 g/hour if aged 60 years or less and at 1.0 g/hour if aged more than 60 years. This regimen has been published elsewhere 5 . The infusion rate was increased by 0.5 g/hour every six hours until cessation of spasms or abolition of the patellar tendon jerk, whichever occurred earlier. The patellar reflex was tested every half hour in the first two hours after the dose was increased and hourly thereafter. Serum magnesium and calcium concentrations were measured every day after commencement of the infusion. After abolition of spasms, the same dose of magnesium was continued for 48 hours before attempting to reduce the dose by 0.5 g/hour. Monitoring included continuous electrocardiography, pulse oximetry, non-invasive blood pressure and urine output monitoring. Twelve-lead electrocardiogram was performed daily to look for magnesium toxicity.
Mechanical ventilation was instituted in cases of excessive sedation with hypoventilation or severe spasms compromising gas exchange. In those who were not able to eat, enteral feeding was provided via nasogastric tube at 35 kcal/kg/day and high protein supplementation at 2 g/kg/day. general management included chest and limb physiotherapy, tracheal suction and skin and mouth care.
If control of spasms could not be achieved by magnesium infusion alone, diazepam was administered as an intravenous infusion starting at 2 mg/hour and titrated to achieve control of spasms. In cases of autonomic dysfunction (unexplained systolic blood pressure >160 mmHg or tachycardia >120 bpm sustained for more than one hour), morphine was given intravenously at 1 mg/hour. In the event of magnesium overdosage, as evidenced by absence of patellar reflex or prolongation of PR interval or serum magnesium level >4 mmol/l, the magnesium infusion was temporarily discontinued and diuresis was induced. Magnesium infusion was recommenced at a lower dosage after return of the patellar reflex. Sedation was scored on the Motor Activity Assessment Scale 13 every eight hours (see Appendix 1 in the online version). The drugs were titrated to avoid excessive sedation and to maintain a score of 2 or 3.
If hypocalcaemia was symptomatic, 10 ml of 10% calcium gluconate was given intravenously. The signs of hypocalcaemia -Chvostek and Trousseau signs -were recorded if present. The primary outcome measure was efficacy of magnesium infusion. This was determined by achievement of control of spasms which was defined as less than two brief spasms within 60 minutes. Secondary outcomes included frequency of autonomic instability, requirement and duration of ventilatory support, hospital stay and mortality.
RESuLTS
Thirty-five adult patients with tetanus were admitted to the intensive care unit during the study period. One patient had developed myoglobinuria and acute renal shutdown on the first day of admission. Another patient had sustained cardiac arrest before admission to the intensive care unit and was on inotropic support. These patients did not receive magnesium therapy. The demographic details and disease characteristics of the remaining 33 patients who were enrolled in the study are shown in Table 1 .
Disease severity was assessed by Ablett scoring 2 (see Appendix 2 in the online version). At presentation, the frequency of severity of tetanus was as follows: grade I: 5 (15%), grade II: 13 (39%), grade III: 14 (42%) and grade IV: 1 (3%) ( Table 2) .
Rigidity and mild spasms were controlled with magnesium therapy alone in six patients (18%); all were grades I and II. These six patients did not require tracheostomy during management. Tracheostomy as well as mechanical ventilation was required in the remaining 27 patients. grading worsened after presentation in three patients with grade I, seven patients with grade II and 10 patients with grade III, totalling 20 patients (63%), and remained static in the rest. Six patients with severe generalised spasms were also not controlled with diazepam infusion and required neuromuscular paralysis with boluses of vecuronium. Sixteen patients developed autonomic instability while on magnesium infusion. The autonomic instability was managed conventionally using vasodilators and inotropes as the situation demanded. The duration and dosage of magnesium and other sedative adjuncts are detailed in Table 3 . we did not observe excessive sedation in patients treated with magnesium alone.
The average duration of ventilatory support required was 18.3±16.0 days whereas the mean hospital stay was 30.8±16.7 days. The overall mortality was 22.9%. Severe autonomic instability with sudden bradycardia and asystole that did not respond to intervention was the cause of death in two patients on magnesium therapy. The Ablett grading (Appendix 2) was used to assess disease severity. remaining patients died of multi-organ failure and acute respiratory distress syndrome secondary to ventilator-associated pneumonia (four) and pulmonary aspiration (two). Though hypocalcaemia was a universal finding during magnesium therapy, none of the patients demonstrated signs of hypocalcaemia. Paralytic ileus was noted in 12 patients -three patients with grade III and nine patients with grade IV severity -and all received magnesium infusion.
DISCuSSION
Intravenous magnesium sulphate infusion helps to control the rigidity and mild spasms in tetanus. In more severe forms of tetanus with generalised and severe spasms, an adjuvant sedative drug is required in addition to magnesium. Attygalle et al 5 had stated that the dose of magnesium required in the very severe form of tetanus may have unacceptable cardiovascular side-effects. By following a strict protocol to avoid such side-effects, while at the same time trying to get the maximum effect of magnesium in the therapeutic range for control of spasms, we have probably shown the most practical and feasible utility of magnesium infusion in tetanus.
Magnesium, being a neuromuscular depressant, is expected to benefit patients with tetanus by controlling rigidity and spasms associated with the disease. Earlier authors have reported the utility of magnesium as the single agent to control spasms of tetanus 4, 5 . However, our series has not supported this conclusion. This may be due to the severe form of disease encountered in our series characterised by severe generalised spasms and autonomic instability. Over three-fourths of our patients (24/33, 78%) had a severe form of tetanus whereas only 15% (six out of 40) of patients had experienced severe illness in the earlier series 5 . we had to use additional sedatives to achieve control of muscle spasms in severe tetanus. However, in mild forms of the disease the benefit was obvious since the rigidity and mild spasms were controlled solely by magnesium infusion, thereby avoiding sedation.
It is reasonable to assume that the therapeutic effect of magnesium on neuromuscular transmission is present in the severe form of tetanus also, but the effect may not be significant enough to control the very severe muscular spasms. In such a scenario, it is possible that magnesium infusion may help to reduce the requirement for conventional sedatives to achieve control of severe spasms. Such a possible benefit offered by magnesium in very severe tetanus could be demonstrated by means of a randomised controlled trial with patients allocated for management with and without magnesium infusion. The disease burden in our centre is not large enough to undertake such a trial to elicit significance. The report by Thwaites et al 3 of the randomised trial from Vietnam had shown these expected advantages, i.e. the dose requirement of sedatives and haemodynamic drugs could be brought down significantly in patients with severe tetanus on magnesium infusion. However, this trial only evaluated magnesium infusion for seven days. The results of this trial are in agreement with our findings that the majority (82%) of patients with severe tetanus required mechanical ventilation.
Conduction disturbances like prolongation of the PQ interval and the widening of the QRS complex begin at serum magnesium concentrations of 3 to 4 mmol/l and proceed to sinoatrial or atrioventricular block at 6 mmol/l 14 . Abolition of the patellar reflex occurs at 4 mmol/l. Thus early changes in electrocardiography correspond to abolition of the patellar reflex. Serious changes in cardiac conduction occur at higher levels and cardiac arrest at 8 mmol/l. Since respiratory depression may not be a life-threatening complication once the patient goes on ventilatory support, hypermagnesaemic effects on the heart would be life-threatening if overlooked. Therefore, our unit monitored the effect on the electrocardiogram to detect effect on the heart.
The study period of two years possibly rules out variations in case-load due to climatic and socioeconomic changes. In the situation of inability to carry out a prospective randomised trial, the next best option would have been to compare the results of the newer intervention to a control group when the therapy was not available or practised (historical controls). This comparison would not be justified in our case as various practices such as availability of human tetanus immunoglobulin, ventilatory strategy for mechanical ventilation and use of infusion pumps for haemodynamic drug delivery were introduced in the preceding years into our unit which would alter the overall outcome of these patients.
In conclusion, our experience with management of tetanus with intravenous magnesium infusion suggests that magnesium may not be useful as the sole agent to control the rigidity and spasms of severe tetanus. Additional sedative adjuncts are required to control the disease.
